Products from BPS Bioscience require a minimum order value above 400€
Background: Integrin beta 6 (ITGB6) is a protein that forms a heterodimer with the integrin alpha v (αv) subunit, creating the integrin αvβ6 complex. ITGB6 is involved in cell adhesion and migration by interacting with the extracellular matrix (ECM). This interaction is essential for tissue repair and regeneration. ITGB6 transduces signals from the ECM to the cell, influencing cell behavior, including proliferation, differentiation, and survival. ITGB6 plays a role in the activation of transforming growth factor-beta (TGF-β), a cytokine involved in immune regulation, cell growth, and differentiation. ITGB6 is often overexpressed in various cancers, including epithelial carcinomas. ITGB6 is implicated in the development of fibrosis in organs such as the lungs, liver, and kidneys. Targeting ITGB6 could help in treating fibrotic diseases by modulating the TGF-β pathway. Overall, ITGB6's role in critical cellular processes and disease mechanisms makes it a promising target for therapeutic interventions in cancer, fibrosis, and potentially other conditions.
Description: SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug, and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE1.
Format: Aqueous buffer solution.
Purity: ≥90%
Storage Stability: Store at -80°C, protect from light.
Target: ITGB6
Uniprot: P18564
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Lyon RP, et al., 2023 Mol Cancer Ther. 22(12):1444-1453.
English
Deutsch
